Association of HBV DNA *** antiviral treatment outcomes in the patients with early-stage HBV-related hepatocellular carcinoma undergoing curative resection

作     者：Jian-Lin Chen Xiao-Jun Lin Qian Zhou Ming Shi Sheng-Ping Li Xiang-Ming Lao 

作者机构：Department of Hepatobiliary OncologyState Key Laboratory of Southern ChinaCollaborative Innovation Center for Cancer MedicineSun Yat-sen University Cancer Center Epidemiology Research UnitThe First Affiliated Hospital of Sun Yat-sen University 

出 版 物：《Chinese Journal of Cancer》 (Chinese Journal of Cancer)

年 卷 期：2016年第35卷第5期

页      面：236-249页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：supported by project grants from the National Natural Science Foundation of China(no.81201603 for Dr.XML) the Guangdong Natural Science Funds(No.S2012010009631 for Dr.XML) the International Program for Ph.D.Candidates from Sun Yat-sen University(for Dr.JLC) 

主　　题：Hepatocellular carcinoma, Resection, Hepatitis B virus, Prognosis, Antiviral therapy 

摘      要：Background:It remains unclear what the antiviral therapy affects disease-free survival(DFS) and overall survival(OS)of patients with hepatitis B virus(HBV)-related hepatocellular carcinoma(HCC) at different tumor stages and baseline HBV DNA *** this study,we analyzed the association of antiviral treatment with DFS and OS based on the stratification of baseline HBV DNA load in early-stage(stages Ⅰ and Ⅱ) HCC ***:We included 445 patients with early-stage HBV-related HCC who underwent curative resection,and then classified them into four subgroups based on baseline HBV DNA load and antiviral therapy *** KaplanMeier and Cox regression analyses were performed to determine the association of clinical characteristics with ***:The median follow-up period was 74 *** all patients,cumulative OS rates in the antiviral group were significantly higher than those in the non-antiviral group(log-rank test,P = 0.023),whereas no significant differences in DFS rates were *** baseline HBV DNA level was a risk factor associated with short DFS and OS in all *** patients with baseline HBV DNA levels ≥2000 lU/mL,antiviral treatment was significantly associated with prolonged DFS and OS(log-rank test,P = 0.041 and 0.001,respectively).In patients with HBV DNA levels 2000 lU/mL or undetectable,antiviral treatment did not show a significant benefit in prolonging DFS and ***:High baseline HBV DNA levels are associated with poor prognosis in the patients with early-stage HCC,and the antiviral treatment could generate survival benefits for the ***,antiviral treatment should be given for these ***,the effect of antiviral treatment on the patients with low viral load remains unclear,and further investigation is warranted.